{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:45:26Z","timestamp":1793123126230,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.lungcan.2023.107253","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T02:35:33Z","timestamp":1684377333000},"page":"107253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands"],"prefix":"10.1016","volume":"181","author":[{"given":"Deirdre M.H.J.","family":"ten Berge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.M.","family":"Damhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-182X","authenticated-orcid":false,"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107253_b0005","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S1470-2045(17)30708-8","article-title":"ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards","volume":"18","author":"Bestvina","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107253_b0010","doi-asserted-by":"crossref","first-page":"100333","DOI":"10.1016\/j.esmoop.2021.100333","article-title":"Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer","volume":"7","author":"Wolf","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2023.107253_b0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"FLAURA Investigators, Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107253_b0020","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.lungcan.2023.107253_b0025","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/curroncol29020057","article-title":"ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date","volume":"29","author":"Gendarme","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0035","doi-asserted-by":"crossref","unstructured":"L. Moliner, E. Arriola, ROS1 non-small cell lung cancer patients treatment approach, Precis. Cancer Med. 4 (2021). doi: 10.21037\/pcm-20-38.","DOI":"10.21037\/pcm-20-38"},{"key":"10.1016\/j.lungcan.2023.107253_b0040","unstructured":"Integraal Kankercentrum Nederland. Landelijke Richtlijn: Niet Kleincellig Longcarcinoom [Netherlands\u2019 national guidelines: non-small cell lung cancer; in Dutch] [Version 2.3]. 2015, (n.d.)."},{"key":"10.1016\/j.lungcan.2023.107253_b0045","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort","volume":"33","author":"Mazi\u00e8res","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0050","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107253_b0055","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/cam4.2972","article-title":"First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer","volume":"9","author":"Shen","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2023.107253_b0060","doi-asserted-by":"crossref","unstructured":"L. Landi, R. Chiari, M. Tiseo, F. D\u2019Inc\u00e0, C. Dazzi, A. Chella, A. Delmonte, L. Bonanno, D. Giannarelli, D.L. Cortinovis, F. de Marinis, G. Borra, A. Morabito, C. Gridelli, D. Galetta, F. Barbieri, F. Grossi, E. Capelletto, G. Minuti, F. Mazzoni, C. Verusio, E. Bria, G. Al\u00ec, R. Bruno, A. Proietti, G. Fontanini, L. Crin\u00f2, F. Cappuzzo, Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 25 (2019) 7312\u20137319. doi: 10.1158\/1078-0432.CCR-19-0994.","DOI":"10.1158\/1078-0432.CCR-19-0994"},{"key":"10.1016\/j.lungcan.2023.107253_b0065","first-page":"1266","article-title":"Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study","volume":"14","author":"Michels","year":"2019","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2023.107253_b0070","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0075","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-019-01164-3","article-title":"Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors","volume":"79","author":"Morris","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.lungcan.2023.107253_b0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lungcan.2019.02.025","article-title":"CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome","volume":"130","author":"Ou","year":"2019","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2023.107253_b0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2022.04.001","article-title":"Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice","volume":"167","author":"Steeghs","year":"2022","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2023.107253_b0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.lungcan.2013.12.010","article-title":"Molecular testing in oncology: Problems, pitfalls and progress","volume":"83","author":"O\u2019Brien","year":"2014","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2023.107253_b0095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcb.24401","article-title":"Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities","volume":"114","author":"Normanno","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.lungcan.2023.107253_b0100","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","article-title":"Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial","volume":"30","author":"Moro-Sibilot","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0105","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jtho.2018.04.016","article-title":"Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer","volume":"13","author":"Li","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11523-019-00636-6","article-title":"Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer in Routine Clinical Practice","volume":"14","author":"Liu","year":"2019","journal-title":"Target. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107253_b0120","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.21037\/jtd.2019.07.44","article-title":"Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis","volume":"11","author":"Masuda","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2023.107253_b0125","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice","volume":"13","author":"Park","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.lungcan.2020.07.016","article-title":"Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study","volume":"147","author":"Zheng","year":"2020","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2023.107253_b0135","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/cer-2021-0131","article-title":"Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC","volume":"10","author":"Doebele","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.lungcan.2023.107253_b0140","doi-asserted-by":"crossref","unstructured":"J.F. Gainor, D. Tseng, S. Yoda, I. Dagogo-Jack, L. Friboulet, J.J. Lin, H.G. Hubbeling, L. Dardaei, A.F. Farago, K.R. Schultz, L.A. Ferris, Z. Piotrowska, J. Hardwick, D. Huang, M. Mino-Kenudson, A.J. Iafrate, A.N. Hata, B.Y. Yeap, A.T. Shaw, Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non\u2013Small-Cell Lung Cancer, JCO Precis. Oncol. 1 (2017) PO.17.00063. doi: 10.1200\/PO.17.00063.","DOI":"10.1200\/PO.17.00063"},{"key":"10.1016\/j.lungcan.2023.107253_b0145","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0150","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3390\/curroncol29030160","article-title":"Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort","volume":"29","author":"Gibson","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2023.107253_b0155","first-page":"103","article-title":"CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer, Lung Cancer Amst","volume":"178","author":"Langston","year":"2023","journal-title":"Neth."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107253_b0160","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223007912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223007912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:25Z","timestamp":1759237525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223007912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":32,"alternative-id":["S0169500223007912"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107253","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107253"}}